ArticleCell communication and signaling : CCS2026
Induction of antiviral RNA interference by avian coronavirus IBV in PBMCs-Mφ.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Infectious bronchitis virus (IBV), a member of the gammacoronavirus family, can easily mutate, resulting in different subtypes of strains. QX and M41, two subtypes of IBV, exhibit distinct characteristics in terms of their pathogenicity and infection site. Immunohistochemistry and qRT–PCR revealed differences in the replication of QX and M41 in different tissues. Interestingly, we found that the viral load of QX steadily increased in “PBMCs-Mφ” chicken macrophages, whereas the opposite phenomenon occurred in the M41 group. We also observed synergistic antiviral effects of interferon and RNA interference (RNAi) on PBMCs-Mφ. Moreover, high-throughput sequencing and vsiRNA analysis revealed only partially detectable vsiRNA (NSP10) in the IBV M41-stimulated group, which explains the above phenomenon. We constructed a PS-vsiRNA plasmid capable of efficiently expressing small RNAs, and the antiviral test results revealed that transfection with PS-M10 significantly reduced the M41 viral load. Moreover, PC-QX-NSP10 and PC-QX-NSP16 overexpression in PBMCs-Mφ showed that the complex of NSP10/NSP16 could effectively reduce the mRNA level of Dicer (an RNAi pathway core enzyme) and increase the viral load, which is a potential viral suppressor of the RNAi (VSR) protein. In summary, for the first time, this study explains the differences between QX and M41 on PBMCs-Mφ from the perspective of vsiRNA in RNAi, which is highly important for the subsequent development of therapeutic IBV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.